<DOC>
	<DOC>NCT01605773</DOC>
	<brief_summary>This trial is conducted in the United States of America (USA). The aim of this trial is to compare the effect of repaglinide on postprandial lipemia in subjects with type 2 diabetes.</brief_summary>
	<brief_title>Effect of Repaglinide on Postprandial Lipemia in Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Repaglinide</mesh_term>
	<mesh_term>Glyburide</mesh_term>
	<criteria>Newly diagnosed patients with type 2 diabetes currently treated with diet and exercise alone (HbA1c below 10%) Subjects with type 2 diabetes treated with sulphonylurea (HbA1c below 8.5%) Males or nonpregnant, nonlactating females Subjects should have normal renal function Type 1 or other specific causes of diabetes Marked symptomatic diabetes Uncontrolled treated/untreated hypertension Known or suspected allergy to the trial products or related products</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>